Loading
Immunotherapy and Immune Responses / CAR-T Cell Therapy Research · Journal article
Acta Crystallographica Section D Structural Biology · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a structural biology study using X-ray crystallography to determine how a single tumor-specific T-cell receptor (TCR 4414A) recognizes a p53 Y220D neoantigen presented on HLA-A2 at atomic resolution. The work demonstrates that the Y220D mutation induces a conformational change in the peptide that enables TCR recognition while maintaining specificity for the mutant over wild-type p53, but does not test whether this recognition translates to therapeutic benefit in adoptive cell therapy or assess the generalizability of the findings.
Structural biology study using X-ray crystallography. Recombinant TCR 4414A, HLA-A2, and p53 peptides (wild-type and Y220D mutant); no human subjects or cells. Intervention: TCR 4414A recognition of p53 Y220D neoepitope. Compared with: Wild-type p53 peptide; structural comparison of mutant and wild-type HLA–peptide complexes.
Y220D mutation induces conformational change in p53 neoepitope that is detected by TCR 4414A TCR 4414A minimizes interactions with N- and C-terminal portions of p53 Y220D (identical in mutant and wild-type) and focuses on the Y220D driver mutation at peptide center TCR 4414A achieves highly specific recognition of mutant over wild-type p53
Structural study; does not assess T-cell function, activation, or cytotoxicity in vitro or in vivo
This work provides mechanistic insight into how T cells discriminate cancer neoantigens from self-antigens at the molecular level, which is foundational to understanding specificity in adoptive T-cell therapy. However, the study does not directly demonstrate clinical efficacy or therapeutic outcomes; it is a mechanistic study that supports the plausibility of TCR-based immunotherapy targeting driver mutations.
A structural biology study using X-ray crystallography to elucidate atomic-level mechanisms of TCR recognition of a cancer neoantigen; mechanistic work that raises questions about TCR specificity rather than testing clinical efficacy or providing definitive evidence for therapeutic application.
As stated by the source record.
This work provides mechanistic insight into how T cells discriminate cancer neoantigens from self-antigens at the molecular level, which is foundational to understanding specificity in adoptive T-cell therapy. However, the study does not directly demonstrate clinical efficacy or therapeutic outcomes; it is a mechanistic study that supports the plausibility of TCR-based immunotherapy targeting driver mutations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Adoptive cell therapy (ACT) with tumor-specific T cells can mediate durable cancer regression. The main target of tumor-specific T cells are neoantigens resulting from mutations in self-antigens over the course of malignant transformation. To understand T-cell recognition of cancer neoantigens at the atomic level, we studied a T-cell receptor (TCR 4414A) that recognizes a neoepitope arising from a driver mutation in the p53 oncogene (p53 Y220D ) presented by HLA-A2. Here, we report the structure of TCR 4414A bound to HLA-A2 and p53 Y220D, as well as structures of unbound wild-type and mutant p53–HLA-A2 ligands. The structures reveal that the Y220D mutation induces a conformational change in the p53 Y220D neoepitope that is detected by TCR 4414A, thereby rendering a normally cryptic self-peptide visible to T cells. The TCR minimizes interactions with the N- and C-terminal portions of p53 Y220D, which are identical in mutant and wild-type peptides, and instead focuses on the Y220D driver mutation at the peptide center. In this way, TCR 4414A achieves highly specific recognition of mutant over wild-type p53, a critical parameter for avoiding off-target toxicities in ACT.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.